Eli Lilly/$LLY
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Eli Lilly
Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio for cancer; Mounjaro, Zepbound, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology.
Ticker
$LLY
Sector
Primary listing
NYSE
Employees
50,000
Headquarters
Website
Eli Lilly Metrics
BasicAdvanced
$841B
40.94
$22.95
0.50
$6.23
0.74%
Price and volume
Market cap
$841B
Beta
0.5
52-week high
$1,133.95
52-week low
$623.78
Average daily volume
2.9M
Dividend rate
$6.23
Financial strength
Current ratio
1.579
Quick ratio
0.777
Long term debt to equity
158.312
Total debt to equity
178.516
Dividend payout ratio (TTM)
26.09%
Interest coverage (TTM)
46.26%
Profitability
EBITDA (TTM)
31,577.733
Gross margin (TTM)
83.04%
Net profit margin (TTM)
31.67%
Operating margin (TTM)
45.56%
Effective tax rate (TTM)
19.79%
Revenue per employee (TTM)
$1,300,000
Management effectiveness
Return on assets (TTM)
19.42%
Return on equity (TTM)
108.28%
Valuation
Price to earnings (TTM)
40.936
Price to revenue (TTM)
12.933
Price to book
35.37
Price to tangible book (TTM)
73.51
Price to free cash flow (TTM)
136.361
Free cash flow yield (TTM)
0.73%
Free cash flow per share (TTM)
6.89
Dividend yield (TTM)
0.66%
Forward dividend yield
0.74%
Growth
Revenue change (TTM)
44.70%
Earnings per share change (TTM)
95.99%
3-year revenue growth (CAGR)
31.69%
10-year revenue growth (CAGR)
12.56%
3-year earnings per share growth (CAGR)
49.27%
10-year earnings per share growth (CAGR)
26.09%
3-year dividend per share growth (CAGR)
15.24%
10-year dividend per share growth (CAGR)
11.61%
What the Analysts think about Eli Lilly
Analyst ratings (Buy, Hold, Sell) for Eli Lilly stock.
Eli Lilly Financial Performance
Revenues and expenses
Eli Lilly Earnings Performance
Company profitability
Eli Lilly News
AllArticlesVideos
Trump policies, China's biotech boom are ending Europe's pharma powerhouse era
CNBC·11 hours ago
Eli Lilly market share drops, Novo Nordisk holds firm as generic weight-loss drugs flood India
CNBC·1 day ago
Eli Lilly's Weight-Loss Pill Hits the Shelves. It's a Turning Point for the Stock.
Barrons·2 days ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Eli Lilly stock?
Eli Lilly (LLY) has a market cap of $841B as of April 11, 2026.
What is the P/E ratio for Eli Lilly stock?
The price to earnings (P/E) ratio for Eli Lilly (LLY) stock is 40.94 as of April 11, 2026.
Does Eli Lilly stock pay dividends?
Yes, the Eli Lilly (LLY) stock pays dividends to shareholders. As of April 11, 2026, the dividend rate is $6.23 and the yield is 0.74%. Eli Lilly has a payout ratio of 26.09% on a trailing twelve-month basis.
When is the next Eli Lilly dividend payment date?
The next Eli Lilly (LLY) dividend payment date is unconfirmed.
What is the beta indicator for Eli Lilly?
Eli Lilly (LLY) has a beta rating of 0.5. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.